Effects of treatment with histone deacetylase inhibitors in solid tumors: A review based on 30 clinical trials

Future Oncology

Volumn 9, Issue 2, 2013, Pages 255-269

  Qiu, Tianzhu ^a   Zhou, Li ^a   Zhu, Wei ^a   Wang, Tongshan ^a   Wang, Jian ^a   Shu, Yongqian ^a   Liu, Ping ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

clinical trial; histone deacetylase inhibitor; solid tumor

Indexed keywords

BELINOSTAT; CARBOPLATIN; CISPLATIN; COSITECAN; CYCLOPHOSPHAMIDE; DEPSIPEPTIDE; DOXORUBICIN; ENTINOSTAT; EPIRUBICIN; ETOPOSIDE; EXEMESTANE; FLUOROURACIL; GEMCITABINE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; IFOSFAMIDE; PACLITAXEL; PANOBINOSTAT; PIVALOYLOXYMETHYL BUTYRATE; PLACEBO; ROMIDEPSIN; TACEDINALINE; TAMOXIFEN; TOPOTECAN; VALPROATE MAGNESIUM; VALPROIC ACID; VINCRISTINE; VORINOSTAT;

ANAPLASTIC GLIOMA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; CONTINUOUS INFUSION; DIFFERENTIATED THYROID CANCER; DNA METHYLATION; DRUG EFFECT; DRUG EFFICACY; EPIGENETIC REPRESSION; EPIGENETICS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEAD CANCER; HISTONE MODIFICATION; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; KIDNEY METASTASIS; LEUKEMIA; LOADING DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; MELANOMA; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NECK CANCER; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEATED DRUG DOSE; REVIEW; SOLID TUMOR; SYSTEMATIC REVIEW; T CELL LYMPHOMA; TESTIS CANCER; THYMIC CARCINOMA; THYMOMA; THYMUS CANCER; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TREATMENT DURATION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 84874094984     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.173     Document Type: Review

References (67)

1. Verma M, Maruvada P, Srivastava S. Epigenetics and cancer. Crit. Rev. Clin. Lab. Sci. 41, 585-607 (2004).
2. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. 25, 269-277 (2000).
3. Nan X, Ng HH, Johnson CA et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393, 386-389 (1998).
4. Glaser KB, Staver MJ, Waring JF et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2, 151-163 (2003).
5. Marks P, RifkindR A, Richon VM et al. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1, 194-202 (2001).
6. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6, 107-116 (2006).
7. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev. 18, 2315-2335 (2004).
8. Pandolfi PP. Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother. Pharmacol. 48(Suppl. 1), S17-S19 (2001).
9. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin. Investig. Drugs. 16, 659-678 (2007).
10. Atadja PW. HDAC inhibitors and cancer therapy. Prog. Drug Res. 67, 175-195 (2011).
11. Venugopal B, Evans TR. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr. Med. Chem. 18, 1658-1671 (2011).
12. Pan LN, Lu J, Huang B. HDAC inhibitors: A potential new category of anti-tumor agents. Cell. Mol. Immunol. 4, 337-343 (2007).
13. Saunders NA, Popa C, Serewko MM et al. Histone deacetylase inhibitors: novel anticancer agents. Expert Opin. Investig. Drugs. 8, 1611-1621 (1999).
14. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl Cancer Inst. 92, 1210-1216 (2000).
15. Candelaria M, Gallardo-Rincón D, Arce C et al. A Phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann. Oncol. 18(9), 1529-1538 (2007).
16. Daud AI, Dawson J, DeConti RC et al. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and Phase I/II clinical trial. Clin. Cancer Res. 15(7), 2479-2487 (2009).
17. Steele NL, Plumb JA, Vidal L et al. A Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res. 14(3), 804-810 (2008).
18. Münster P, Marchion D, Bicaku E et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: A clinical and translational study. J. Clin. Oncol. 25, 1979-1985 (2007).
19. Fujiwara Y, Yamamoto N, Yamada Y et al. Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Sci. 100(9), 1728-1734 (2009).
20. Razak AR, Hotte SJ, Siu LL et al. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br. J. Cancer 104(5), 756-762 (2011).
21. de Bono JS, Kristeleit R, Tolcher A et al. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin. Cancer Res. 14(20), 6663-6673 (2008).
22. Hallas J, Friis S, Bjerrum L et al. Cancer risk in long-term users of valproate: A population-based case-control study. Cancer Epidemiol. Biomarkers 18, 1714-1719 (2009).
23. Stadler WM, Margolin K, Ferber S et al. A Phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer 5, 57-60 (2006).
24. Hainsworth JD, Infante JR, Spigel DR et al. A Phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest. 29, 451-455 (2011).
25. Modesitt SC, Sill M, Hoffman JS et al. A Phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol. Oncol. 109, 182-186 (2008).
26. Mackay HJ, Hirte H, Colgan T et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur. J. Cancer. 46, 1573-1579 (2010).
27. Schrump DS, Fischette MR, Nguyen DM et al. Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin. Cancer Res. 14, 188-198 (2008).
28. Vansteenkiste J, Van Cutsem E, Dumez H et al. Early Phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest. New Drugs 26, 483-488 (2008).
29. Reid T, Valone F, Lipera W et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 45, 381-386 (2004).
30. Traynor AM, Dubey S, Eickhoff JC et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: A Wisconsin Oncology Network Phase II study. J. Thorac. Oncol. 4, 522-526 (2009).
31. Otterson GA, Hodgson L, Pang H et al. Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J. Thorac. Oncol. 5, 1644-1648 (2010).
32. Ramalingam SS, Maitland ML, Frankel P et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 56-62 (2010).
33. Woyach JA, Kloos RT, Ringel MD et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J. Clin. Endocrinol. Metab. 94(1), 164-170 (2009).
34. Hauschild A, Trefzer U, Garbe C et al. Multicenter Phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]- benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res. 18, 274-278 (2008).
35. Whitehead RP, Rankin C, Hoff PM et al. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: A Southwest Oncology Group study (S0336). Invest. New Drugs 27, 469-475 (2009).
36. Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest. New Drugs 26, 81-87 (2008).
37. Galanis E, Jaeckle KA, Maurer MJ et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: A north central cancer treatment group study. J. Clin. Oncol. 27, 2052-2058 (2009).
38. Iwamoto FM, Lamborn KR, Kuhn JG et al. A Phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro. Oncol. 13, 509-516 (2011).
39. Wolff JE, Kramm C, Kortmann RD et al. Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J. Neurooncol. 90, 309-314 (2008).
40. Molife LR, Attard G, Fong PC et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann. Oncol. 21, 109-113 (2010).
41. Bradley D, Rathkopf D, Dunn R et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (NCI Trial # 6862): trial results and interleukin-6 analysis: A study by the DOD Prostate Cancer Clinical Trial Consortium and University of Chicago Phase II Consortium. Cancer 115, 5541-5549 (2009).
42. Ramalingam SS, Belani CP, Ruel C et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J. Thorac. Oncol. 4, 97-101 (2009).
43. Scherpereel A, Berghmans T, Lafitte JJ et al. Valproate-doxorubicin: promising therapy for progressing mesothelioma. A Phase II study. Eur. Respir. J. 37, 129-135 (2011).
44. Giaccone G, Rajan A, Berman A et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J. Clin. Oncol. 29, 2052-2059 (2011).
45. Munster PN, Thurn KT, Thomas S et al. A Phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br. J. Cancer 104, 1828-1835 (2011).
46. Munster P, Marchion D, Bicaku E et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: Phase I/II trial of valproic acid and epirubicin/FEC. Clin. Cancer Res. 15, 2488-2496 (2009).
47. Arce C, Pérez-Plasencia C, González-Fierro A et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One. e98 (2006).
48. Shah MH, Binkley P, Chan K et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 12, 3997-4003 (2006).
49. Coronel J, Cetina L, Pacheco I et al. A double-blind, placebo-controlled, randomized Phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med. Oncol. 28(Suppl. 1), S540-S546 (2010).
50. Richards DA, Boehm KA, Waterhouse DM et al. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a Phase II randomized, double-blind, placebo-controlled, multicenter study. Ann. Oncol. 17, 1096-1102 (2006).
51. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer. Inst. 92, 205-216 (2000).
52. Schrump DS, Nguyen DM. Targeting the epigenome for the treatment and prevention of lung cancer. Semin Oncol. 32, 488-502 (2005).
53. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769-784 (2006).
54. Baylin SB, Esteller M, Rountree MR et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet.10, 687-692 (2001).
55. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4, 13-18 (2003).
56. Kelly WK, Marks PA. Drug insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat. Clin. Pract. Oncol. 2, 150-157 (2005).
57. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 5, 981-989 (2007).
58. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J. Cell Biochem. 107, 600-608 (2009).
59. Burgess A, Ruefli A, Beamish H et al. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 23, 6693-6701 (2004).
60. Carey N, La Thangue NB. Histone deacetylase inhibitors: gathering pace. Curr. Opin. Pharmacol. 6, 369-375 (2006).
61. Peart MJ, Smyth GK, van Laar RK et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 3697-3702 (2005).
62. Yu X, Guo ZS, Marcu MG et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl Cancer Inst. 94, 504-513 (2002).
63. Yu XD, Wang SY, Chen GA et al. Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells. Cancer J. 13, 105-13 (2007).
64. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38-51 (2006).
65. Fantin VR, Richon VM. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin. Cancer Res. 13, 7237-7242 (2007).
66. Piekarz RL, Frye R, Prince HM et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117, 5827-5834 (2011).
67. O'Connor OA, Heaney ML, Schwartz L et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 24, 166-173 (2006).